Sreeram Yalamanchili
Greenville, NCNPI 1457980864
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,401 of the $6,935 with a category attached, or 63.5%. It is spread thinly across 22 manufacturers, the largest accounting for just 19.7%. 2025 is the largest year on record at $5,117, more than ten times the $126 reported in 2023.
Across 74 payments — averaging $93.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$1K
- Boston Scientific$1K
- Philips North America LLC$1K
- Stryker$680
- Abbott$435
- Amgen$333
- plus $2K from 16 others
What the payments were for
- Travel & lodging$2,26833%
- Food & beverage$4,40163%
- Education$2664%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 16 | $1,366 |
| Boston Scientific | 5 | $1,113 |
| Philips North America LLC | 6 | $1,057 |
| Stryker | 3 | $680 |
| Abbott | 3 | $435 |
| Amgen | 5 | $333 |
| Medtronic | 5 | $286 |
| Novo Nordisk | 4 | $280 |
| Recor Medical Inc | 1 | $184 |
| Terumo Medical Corporation | 2 | $169 |
| Biotronik Inc. | 3 | $164 |
| Bridgebio Pharma, Inc. | 1 | $148 |
| Novartis | 6 | $144 |
| Boehringer Ingelheim | 2 | $132 |
| AstraZeneca | 1 | $125 |
| Vital Connect, Inc | 2 | $112 |
| Johnson & Johnson | 4 | $66 |
| Angiodynamics, Inc. | 1 | $60 |
| Cardiva Medical, Inc. | 1 | $24 |
| Janssen Scientific Affairs, LLC | 1 | $23 |
| Bayer | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Farapulse$976
- (9520) IGT Devices Undivided$967
- CT THROMBECTOMY SYSTEM KIT$341
- FLOWTRIEVER CATHETER, S$341
- CLOTTRIEVER BOLD CATHETER$339
- ENSITE$266
- Paradise Ultrasound Renal Denervation System$184
- SYMPLICITY G3$148
- Attruby$148
- Impella$145
- OPTIS$132
- JARDIANCE$125
- Wegovy$125
- WAINUA$125
- ACCOLADE SR$125
- Optitorque$105
- ANGIO-SEAL$105
- GlideWire$105
- METACROSS OTW$105
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 62 | $65,861 |
| EntrestoSacubitril/Valsartan | 31 | $39,578 |
| FarxigaDapagliflozin Propanediol | 28 | $28,461 |
| JardianceEmpagliflozin | 20 | $16,225 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,919 |
| Ranolazine ErRanolazine | 34 | $1,269 |
| Atorvastatin Calcium | 70 | $1,241 |
| Metoprolol Succinate | 58 | $834 |
| Valsartan | 23 | $629 |
| Ezetimibe | 21 | $414 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 39 | $262 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $226 |
| Torsemide | 15 | $219 |
| Furosemide | 48 | $191 |
| Spironolactone | 31 | $178 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $144 | $39,57831 claims |
| AstraZenecaFarxiga | $125 | $28,46128 claims |
| Boehringer IngelheimJardiance | $132 | $16,22520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in North Carolinaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.